Gilead Sciences, Inc. (Nasdaq: GILD) today shared positive data from the Phase 3 ASCENT-03 study demonstrating a highly statistically significant and clinically meaningful improvement in ...

Multitude Therapeutics, Inc., a clinical stage biopharmaceutical company focused on the development of ADC drugs, today announced interim results from its ongoing Phase I/II open-label, multicenter ...

Look Up Hong Kong, a new parent-led group launched to unite families for healthier, happier childhoods in the digital age, is leading a movement to advocate for delayed smartphone and social media use ...

The West Virginia Mountaineers and UCF Knights will fight Saturday afternoon for their first Big 12 Conference win this ...

BERLIN -- For the first time in a phase III trial, adjuvant treatment with a CDK4/6 inhibitor significantly improved overall ...

Given the intricate nature of these technologies, enforcing detailed, granular standards throughout the development lifecycle ...

Third Quarter 2025 HighlightsNet income for the third quarter of 2025 was $9.7 million, compared to $10.4 million in the prior quarter and $9.5 ...

Greater disease activity and higher proteinuria levels were associated with a greater risk for VTE among patients with LN.

T-cell engagers, especially BiTEs, show promise in treating solid tumors by targeting tumor-associated antigens and redirecting T-cell activity. Tarlatamab, targeting DLL3 in SCLC, demonstrated ...

Graduates of the Adult Practical Nursing Program at Schuylkill Technology Center North achieved an outstanding rating on the National Council Licensure Examination, officials announced. The 24 ...

Ranging in age from a tender 25 to a seasoned 39, this year’s GenNext Awards honorees work in a range of disciplines at a ...

WINSTON-SALEM, NC / ACCESS Newswire / October 14, 2025 / Retail fixture leader Imageworks Display© will unveil a dramatically ...